Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
Vasopressin
The body's own antidiuretic nonapeptide, used intravenously in intensive care to support blood pressure in vasodilatory shock.
Terlipressin
A vasopressin analogue approved intravenously for hepatorenal syndrome — with a boxed warning about serious or fatal respiratory failure.
How far human research has progressed
Vasopressin
Approved critical-care medicineTerlipressin
Approved narrow-indication hospital medicineClaim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
Vasopressin
Not separately assessed; see the full profile.Terlipressin
Not separately assessed; see the full profile.Human research context
Vasopressin
Approved critical-care medicineTerlipressin
Approved narrow-indication hospital medicineHuman efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
Vasopressin
Terlipressin
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
Vasopressin
Terlipressin
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
Vasopressin
Terlipressin
Regulatory status (legal position, not proof it works)
Vasopressin
Named regulators: FDA (US)
Approved IV vasopressin products (e.g. Vasostrict) are indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Approval is specific to that critical-care context.
Terlipressin
Named regulators: FDA (US)
FDA-approved (Terlivaz) to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. The label carries a boxed warning for serious or fatal respiratory failure.
Common claims
Vasopressin
- · Raises blood pressure in vasodilatory (e.g. septic) shock
- · Reduces catecholamine requirements in critical care
Terlipressin
- · Improves kidney function in hepatorenal syndrome
How settled our evidence rating is
Vasopressin
Terlipressin
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
Vasopressin
No established human cancer signal within approved use.Terlipressin
No established human cancer signal within approved use.What this adds up to, in plain English
Vasopressin
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.Terlipressin
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.A comparison is not a recommendation